[1]
Owen RT. Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin. Drugs of today (Barcelona, Spain : 1998). 2009 Apr:45(4):261-7. doi: 10.1358/dot.2009.45.4.1358835. Epub
[PubMed PMID: 19499091]
[2]
Wu J, Chang F, Zu H. Efficacy and safety evaluation of citalopram and doxepin on sleep quality in comorbid insomnia and anxiety disorders. Experimental and therapeutic medicine. 2015 Oct:10(4):1303-1308
[PubMed PMID: 26622482]
Level 2 (mid-level) evidence
[3]
Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: A systematic review. Journal of the American Academy of Dermatology. 2017 Dec:77(6):1068-1073.e7. doi: 10.1016/j.jaad.2017.08.025. Epub 2017 Oct 21
[PubMed PMID: 29033248]
Level 1 (high-level) evidence
[4]
Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. Journal of drugs in dermatology : JDD. 2010 Aug:9(8):992-7
[PubMed PMID: 20684150]
[5]
Ju T, Vander Does A, Mohsin N, Yosipovitch G. Lichen Simplex Chronicus Itch: An Update. Acta dermato-venereologica. 2022 Oct 19:102():adv00796. doi: 10.2340/actadv.v102.4367. Epub 2022 Oct 19
[PubMed PMID: 36250769]
[6]
Wörz R, Berlin J. [Treatment of chronic pain syndromes with antidepressants.]. Schmerz (Berlin, Germany). 1989 Mar:3(1):1-7
[PubMed PMID: 18415335]
[7]
Casale R, Symeonidou Z, Bartolo M. Topical Treatments for Localized Neuropathic Pain. Current pain and headache reports. 2017 Mar:21(3):15. doi: 10.1007/s11916-017-0615-y. Epub
[PubMed PMID: 28271334]
[8]
Hershey LA, Bednarczyk EM. Treatment of headache in the elderly. Current treatment options in neurology. 2013 Feb:15(1):56-62. doi: 10.1007/s11940-012-0205-6. Epub
[PubMed PMID: 23054583]
[9]
Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Current pain and headache reports. 2003 Feb:7(1):51-4
[PubMed PMID: 12525271]
[10]
Sandig AG, Campmany AC, Campos FF, Villena MJ, Naveros BC. Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsions for an analgesic and anti-allodynic activity: development, characterization and in vivo evaluation. Colloids and surfaces. B, Biointerfaces. 2013 Mar 1:103():558-65. doi: 10.1016/j.colsurfb.2012.10.061. Epub 2012 Nov 16
[PubMed PMID: 23261580]
[11]
McCleane G. Topical application of the tricyclic antidepressant doxepin can reduce dysuria and frequency. Scandinavian journal of urology and nephrology. 2004:38(1):88-9
[PubMed PMID: 15204434]
[12]
Feighner JP. Mechanism of action of antidepressant medications. The Journal of clinical psychiatry. 1999:60 Suppl 4():4-11; discussion 12-3
[PubMed PMID: 10086478]
[13]
Kołodziej M, Majewska M, Krajewska A, Szponar J. [Prolonged toxic coma and anisocoria secondary to doxepin, lorazepam and phenobarbital poisoning--case study]. Przeglad lekarski. 2012:69(8):624-6
[PubMed PMID: 23243948]
Level 3 (low-level) evidence
[14]
Pozderac I, Lugović-Mihić L, Artuković M, Stipić-Marković A, Kuna M, Ferček I. Chronic inducible urticaria: classification and prominent features of physical and non-physical types. Acta dermatovenerologica Alpina, Pannonica, et Adriatica. 2020 Sep:29(3):141-148
[PubMed PMID: 32975301]
[15]
Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct:12(7):571-80
[PubMed PMID: 12360109]
[16]
Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK. Absolute bioavailability and stereoselective pharmacokinetics of doxepin. Xenobiotica; the fate of foreign compounds in biological systems. 2002 Jul:32(7):615-23
[PubMed PMID: 12162857]
[17]
Leppert W, Malec-Milewska M, Zajaczkowska R, Wordliczek J. Transdermal and Topical Drug Administration in the Treatment of Pain. Molecules (Basel, Switzerland). 2018 Mar 17:23(3):. doi: 10.3390/molecules23030681. Epub 2018 Mar 17
[PubMed PMID: 29562618]
[18]
Gimeno A, Calpena AC, Sanz R, Mallandrich M, Peraire C, Clares B. Transbuccal delivery of doxepin: studies on permeation and histological investigation. International journal of pharmaceutics. 2014 Dec 30:477(1-2):650-4. doi: 10.1016/j.ijpharm.2014.10.060. Epub 2014 Nov 1
[PubMed PMID: 25445535]
[20]
Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, Sheikh J, Weldon D, Zuraw B, Bernstein DI, Blessing-Moore J, Cox L, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D. The diagnosis and management of acute and chronic urticaria: 2014 update. The Journal of allergy and clinical immunology. 2014 May:133(5):1270-7. doi: 10.1016/j.jaci.2014.02.036. Epub
[PubMed PMID: 24766875]
[21]
Özkaya E, Babuna Kobaner G, Yılmaz Z, Kutlay A. Doxepin in difficult-to-treat chronic urticaria: A retrospective, cross-sectional study from Turkey. Dermatologic therapy. 2019 Jul:32(4):e12993. doi: 10.1111/dth.12993. Epub 2019 Jul 14
[PubMed PMID: 31175673]
Level 2 (mid-level) evidence
[22]
Creeley CE, Denton LK. Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes. Brain sciences. 2019 Sep 14:9(9):. doi: 10.3390/brainsci9090235. Epub 2019 Sep 14
[PubMed PMID: 31540060]
Level 1 (high-level) evidence
[24]
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Apr:67(4):674-694. doi: 10.1111/jgs.15767. Epub 2019 Jan 29
[PubMed PMID: 30693946]
[25]
Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. Journal of the American Pharmacists Association : JAPhA. 2012:52(6):e210-9. doi: 10.1331/JAPhA.2012.12051. Epub
[PubMed PMID: 23229983]
[26]
Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep medicine reviews. 2015 Feb:19():75-83. doi: 10.1016/j.smrv.2014.06.001. Epub 2014 Jun 19
[PubMed PMID: 25047681]
Level 1 (high-level) evidence
[27]
Sep-Kowalikowa B, Prokopowicz A, Pankiewicz P. [Weight gain during antidepressant therapy]. Psychiatria polska. 1992 Jan-Apr:26(1-2):37-43
[PubMed PMID: 1298003]
[28]
Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Is doxepin a safer tricyclic for the heart? The Journal of clinical psychiatry. 1991 Aug:52(8):338-41
[PubMed PMID: 1869496]
[29]
Feighner J, Hendrickson G, Miller L, Stern W. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. Journal of clinical psychopharmacology. 1986 Feb:6(1):27-32
[PubMed PMID: 3081600]
Level 1 (high-level) evidence
[30]
Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. The Journal of clinical psychiatry. 1985 Mar:46(3 Pt 2):20-5
[PubMed PMID: 3882676]
Level 2 (mid-level) evidence
[31]
Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J, Irvine MJ. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. Journal of clinical psychopharmacology. 1997 Feb:17(1):15-21
[PubMed PMID: 9004052]
[32]
Isacsson G, Rich CL. Antidepressant drugs and the risk of suicide in children and adolescents. Paediatric drugs. 2014 Apr:16(2):115-22. doi: 10.1007/s40272-013-0061-1. Epub
[PubMed PMID: 24452997]
[33]
Armbrust S, Nikischin W, Rochholz G, Franzelius C, Bielstein A, Kramer HH. Hypothermia in a combined intoxication with doxepin and moclobemide in an adolescent. Forensic science international. 2010 Feb 25:195(1-3):e1-3. doi: 10.1016/j.forsciint.2009.10.017. Epub 2010 Jan 13
[PubMed PMID: 20074878]
[34]
Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. Journal of neurology. 2000 Oct:247(10):811
[PubMed PMID: 11127542]
[35]
Thomas SJ, Shin M, McInnis MG, Bostwick JR. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015 Apr:35(4):433-49. doi: 10.1002/phar.1576. Epub
[PubMed PMID: 25884531]
[36]
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinical pharmacology and therapeutics. 2017 Jul:102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13
[PubMed PMID: 27997040]
[37]
Masbough F, Roshanzamiri S, Rahimi M, Sahraei Z, Evini PET. Serotonin syndrome due to concomitant use of linezolid and methadone. Clinical case reports. 2022 Nov:10(11):e6341. doi: 10.1002/ccr3.6341. Epub 2022 Nov 5
[PubMed PMID: 36381053]
Level 3 (low-level) evidence
[38]
Campleman SL, Brent J, Pizon AF, Shulman J, Wax P, Manini AF, Toxicology Investigators’ Consortium (ToxIC). Drug-specific risk of severe QT prolongation following acute drug overdose. Clinical toxicology (Philadelphia, Pa.). 2020 Dec:58(12):1326-1334. doi: 10.1080/15563650.2020.1746330. Epub 2020 Apr 7
[PubMed PMID: 32252558]
[39]
Rademacher S, Dietz R, Haverkamp W. QT prolongation and syncope with methadone, doxepin, and a beta-blocker. The Annals of pharmacotherapy. 2005 Oct:39(10):1762-3
[PubMed PMID: 16144878]
[40]
Hassinger AB, Bletnisky N, Dudekula R, El-Solh AA. Selecting a pharmacotherapy regimen for patients with chronic insomnia. Expert opinion on pharmacotherapy. 2020 Jun:21(9):1035-1043. doi: 10.1080/14656566.2020.1743265. Epub 2020 Mar 23
[PubMed PMID: 32202451]
Level 3 (low-level) evidence
[41]
. Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics. Prescrire international. 2001 Feb:10(51):25-31
[PubMed PMID: 11503857]
[42]
Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. The Medical journal of Australia. 2007 Sep 17:187(6):361-5
[PubMed PMID: 17874986]
[43]
Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Archives of general psychiatry. 1981 Jul:38(7):815-20
[PubMed PMID: 7247643]
[44]
Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, Lüderitz B, Rao ML. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Therapeutic drug monitoring. 2001 Aug:23(4):435-40
[PubMed PMID: 11477329]
[45]
Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clinical obstetrics and gynecology. 2009 Sep:52(3):483-97. doi: 10.1097/GRF.0b013e3181b52bd6. Epub
[PubMed PMID: 19661763]
[46]
Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. American journal of therapeutics. 2021 Jan-Feb 01:28(1):e118-e126. doi: 10.1097/MJT.0000000000000909. Epub
[PubMed PMID: 30601177]
[47]
Fiaturi N, Greenblatt DJ. Therapeutic Drug Monitoring of Antidepressants. Handbook of experimental pharmacology. 2019:250():115-133. doi: 10.1007/164_2018_161. Epub
[PubMed PMID: 30194543]
[48]
Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Doxepin plasma concentrations: is there really a therapeutic range? Journal of clinical psychopharmacology. 2001 Aug:21(4):432-9
[PubMed PMID: 11476128]
[49]
Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003 May:36(3):98-104
[PubMed PMID: 12806567]
[50]
White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2008 Dec:4(4):238-50
[PubMed PMID: 19031375]
Level 2 (mid-level) evidence
[51]
Henry JA. A fatal toxicity index for antidepressant poisoning. Acta psychiatrica Scandinavica. Supplementum. 1989:354():37-45
[PubMed PMID: 2589102]
[52]
Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, Kapur N. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. The British journal of psychiatry : the journal of mental science. 2010 May:196(5):354-8. doi: 10.1192/bjp.bp.109.070219. Epub
[PubMed PMID: 20435959]
[53]
Brennan FJ. Electrophysiologic effects of imipramine and doxepin on normal and depressed cardiac Purkinje fibers. The American journal of cardiology. 1980 Oct:46(4):599-606
[PubMed PMID: 7416020]
[54]
Giardina EG, Cooper TB, Suckow R, Saroff AL. Cardiovascular effects of doxepin in cardiac patients with ventricular arrhythmias. Clinical pharmacology and therapeutics. 1987 Jul:42(1):20-7
[PubMed PMID: 3595065]
[55]
Sakka SG, Kuethe F, Demme U, Hüttemann E. [Intoxication with a tricyclic antidepressant]. Der Anaesthesist. 2007 Jun:56(6):581-6
[PubMed PMID: 17464486]
[56]
Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel RR, Schmidt LG. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004 Mar:37 Suppl 1():S39-45
[PubMed PMID: 15052513]
[57]
Diltoer MW, Poelmans LW, Hubloue I, Spapen HD, Maes V, Huyghens LP. Combined intoxication with a tricyclic antidepressive agent and a neuroleptic. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. 1996 Mar:3(1):52-5
[PubMed PMID: 8886672]
[58]
Frank RD, Kierdorf HP. Is there a role for hemoperfusion/hemodialysis as a treatment option in severe tricyclic antidepressant intoxication? The International journal of artificial organs. 2000 Sep:23(9):618-23
[PubMed PMID: 11059884]
[59]
Mirrakhimov AE, Ayach T, Barbaryan A, Talari G, Chadha R, Gray A. The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions. International journal of nephrology. 2017:2017():7831358. doi: 10.1155/2017/7831358. Epub 2017 Aug 8
[PubMed PMID: 28932601]
[60]
Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Medical care. 2005 Dec:43(12):1203-7
[PubMed PMID: 16299431]